A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
Liang, S.; Tran, E.; Du, X.; Dong, J.; Sudholz, H.; Chen, H.; Qu, Z.; Huntington, N.; Babon, J.; Kershaw, N.; Zhang, Z.-Y.; Baell, J.; Wiede, F.; Tiganis, T.
Show abstract
The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a PTP1B/PTPN2 inhibitor in clinical trials for solid tumors. Here we have explored the therapeutic potential of a related small-molecule-inhibitor, Compound-182. We demonstrate that Compound-182 is a highly potent and selective active site competitive inhibitor of PTP1B and PTPN2 that enhances T cell recruitment and activation and represses the growth of tumors in mice, without promoting overt immune-related toxicities. The enhanced anti-tumor immunity in immunogenic tumors could be ascribed to the inhibition of PTP1B/PTPN2 in T cells, whereas in cold tumors, Compound-182 elicited direct effects on both tumor cells and T cells. Importantly, treatment with Compound-182 rendered otherwise resistant tumors sensitive to -PD1 therapy. Our findings establish the potential for small molecule inhibitors of PTP1B and PTPN2 to enhance anti-tumor immunity and combat cancer.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Discovery of a new class of reversible TEA-domain transcription factor inhibitors with a novel binding mode 96%
- A novel triptolide analog downregulates NF-κB and induces mitochondrial apoptosis pathways in human pancreatic cancer 95%
- Affinity-guided labeling reveals P2X7 nanoscale membrane redistribution during BV2 microglial activation 95%
Similar papers in this journal
- Intratumor Childhood Vaccine-Specific CD4+ T cell Recall Coordinates Antitumor CD8+ T cells and Eosinophils 94%
- Distinct sets of molecular characteristics define tumor-rejecting neoantigens 94%
- Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion 93%
Similar papers in this journal
- A genome-scale drug discovery pipeline uncovers new therapeutic targets and a unique p97 allosteric binding site in Schistosoma mansoni 95%
- A Targeted Combination Therapy Achieves Effective Pancreatic Cancer Regression And Prevents Tumor Resistance 95%
- Structural basis for stereospecific inhibition of ASCT2 from rational design 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.